Publikationen (68) Publikationen von URSULA VERDALLÉS GUZMÁN

filter_list

2025

  1. Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression

    Clinical Journal of the American Society of Nephrology, Vol. 20, Núm. 5, pp. 632-641

  2. Comparative Analysis of Proteinuria and Longitudinal Outcomes in Immune Complex Membranoproliferative Glomerulonephritis and C3 Glomerulopathy

    Kidney International Reports, Vol. 10, Núm. 4, pp. 1223-1236

  3. Comparative Analysis of Proteinuria and Longitudinal Outcomes in Immune Complex Membranoproliferative Glomerulonephritis and C3 Glomerulopathy

    Kidney International Reports, Vol. 10, Núm. 4, pp. 1223-1236

2024

  1. Renin–angiotensin–aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial

    Hipertensión y riesgo vascular, Vol. 41, Núm. 2, pp. 95-103

  2. Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis

    Nephrology Dialysis Transplantation, Vol. 39, Núm. 2, pp. 328-340

  3. Tubular biomarkers and histology in lupus nephritis

    International Journal of Rheumatic Diseases, Vol. 27, Núm. 6

  4. Tubular biomarkers in proteinuric kidney disease: histology correlation and kidney prognosis of tubular biomarkers

    Clinical Kidney Journal, Vol. 17, Núm. 5

2023

  1. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine, Vol. 29, Núm. 7, pp. 1867-1876

  2. Obesity, chronic kidney disease progression and the role of the adipokine C1q/TNF related protein-3

    Nefrologia, Vol. 43, Núm. 3, pp. 328-334

  3. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

    The Lancet, Vol. 401, Núm. 10388, pp. 1584-1594

2021

  1. A case of ANCA-associated vasculitis after AZD1222 (Oxford–AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?

    Kidney International

  2. Obesity related risk for chronic kidney disease progression and cardiovascular disease after propensity score matching

    Hipertension y Riesgo Vascular, Vol. 38, Núm. 2, pp. 63-71

  3. Renal long-term outcome of critically ill COVID-19 patients with acute kidney failure and continuous renal replacement therapy

    Clinical Kidney Journal

  4. Riesgo relacionado con la obesidad para la progresión de insuficiencia renal crónica y enfermedad cardiovascular tras emparejamiento por puntaje de propensión

    Hipertensión y riesgo vascular, Vol. 38, Núm. 2, pp. 63-71

  5. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

    Kidney International, Vol. 99, Núm. 4, pp. 986-998

  6. Use of renin–angiotensin–aldosterone system blockade in controversial chronic kidney disease populations

    Medicina Clinica, Vol. 156, Núm. 11, pp. 561-567

2020

  1. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain

    Kidney International

  2. Chronic kidney disease progression in patients with resistant hypertension subject to 2 therapeutic strategies: Intensification with loop diuretics vs aldosterone antagonists

    Nefrologia, Vol. 40, Núm. 1, pp. 66-74

  3. Progresión de la enfermedad renal crónica en pacientes con hipertensión resistente sometidos a 2 estrategias terapéuticas: intensificación con diuréticos de asa vs. antagonistas de la aldosterona

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 40, Núm. 1, pp. 65-73

  4. The effect of renin–angiotensin–aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design

    Hipertensión y riesgo vascular, Vol. 37, Núm. 3, pp. 101-107